These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 3568303)

  • 1. Cardiovascular effects of verapamil in patients with essential hypertension.
    Schmieder RE; Messerli FH; Garavaglia GE; Nunez BD
    Circulation; 1987 May; 75(5):1030-6. PubMed ID: 3568303
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long term effects of sustained release verapamil on the renal and systemic haemodynamic parameters in hypertensive patients with mild to severe chronic renal failure.
    Schohn DC; Jahn HA; Maareck M
    Drugs; 1993; 46 Suppl 2():113-9; discussion 119-20. PubMed ID: 7512464
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiovascular effects of a trandolapril/verapamil combination in patients with mild to moderate essential hypertension.
    Aepfelbacher FC; Messerli FH; Nunez E; Michalewicz L
    Am J Cardiol; 1997 Mar; 79(6):826-8. PubMed ID: 9070574
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fixed combination trandolapril/verapamil sustained-release: a review of its use in essential hypertension.
    Muijsers RB; Curran MP; Perry CM
    Drugs; 2002; 62(17):2539-67. PubMed ID: 12421112
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the electrophysiologic effects of oral sustained-release and intravenous verapamil in patients with paroxysmal supraventricular tachycardia.
    Lai WT; Voon WC; Yen HW; Chang JS; Sheu SH; Hwang YS; Chiu HF
    Am J Cardiol; 1993 Feb; 71(5):405-8. PubMed ID: 8430627
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Plasma levels and noninvasive hemodynamic profile of slow release verapamil (240 mg). A multicenter study].
    Vulpis V; Seccia TM; Ricci S; Pirrelli A
    Riv Eur Sci Med Farmacol; 1993; 15(5-6):227-35. PubMed ID: 7761676
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiovascular effects of isradipine in essential hypertension.
    Grossman E; Messerli FH; Oren S; Nunez B; Garavaglia GE
    Am J Cardiol; 1991 Jul; 68(1):65-70. PubMed ID: 1829320
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immediate and short-term cardiovascular effects of fosinopril, a new angiotensin-converting enzyme inhibitor, in patients with essential hypertension.
    Oren S; Messerli FH; Grossman E; Garavaglia GE; Frohlich ED
    J Am Coll Cardiol; 1991 Apr; 17(5):1183-7. PubMed ID: 1826120
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exercise hemodynamics and oxygen delivery in human hypertension. Response to verapamil.
    Cody RJ; Kubo SH; Covit AB; Müller FB; Lopez-Ovejero J; Laragh JH
    Hypertension; 1986 Jan; 8(1):3-10. PubMed ID: 3943884
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Favourable interaction of calcium antagonist plus ACE inhibitor on cardiac haemodynamics in treating hypertension: rest and effort evaluation.
    Di Somma S; Carotenuto A; de Divitiis M; Paulucci A; Galderisi M; Cuocolo A; de Divitiis O
    J Hum Hypertens; 1995 Mar; 9(3):163-8. PubMed ID: 7783096
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of verapamil SR 240 mg in essential hypertension: results of a multicentric phase IV study.
    Speders S; Sosna J; Schumacher A; Pfennigsdorf G
    J Cardiovasc Pharmacol; 1989; 13 Suppl 4():S47-9. PubMed ID: 2475686
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The hemodynamics of calcium-channel antagonists in hypertension: vascular and myocardial responses.
    Cody RJ
    Circulation; 1987 Jan; 75(1 Pt 2):I175-9. PubMed ID: 3791618
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conversion from sustained-release to immediate-release calcium entry blockers: outcome in patients with mild-to-moderate hypertension.
    Hilleman DE; Mohiuddin SM; Lucas BD; Shinn B; Elsasser GN
    Clin Ther; 1993; 15(6):1002-10. PubMed ID: 8111798
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immediate and short-term hemodynamic effects of diltiazem in patients with hypertension.
    Amodeo C; Kobrin I; Ventura HO; Messerli FH; Frohlich ED
    Circulation; 1986 Jan; 73(1):108-13. PubMed ID: 3510085
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of sustained-release verapamil: automatic ambulatory blood pressure monitoring.
    Zachariah PK; Sheps SG; Schriger A
    J Clin Hypertens; 1986 Sep; 2(3 Suppl):133S-142S. PubMed ID: 3540223
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Left ventricular diastolic filling improvement obtained by intravenous verapamil in mild to moderate essential hypertension: a complex effect.
    Franchi F; Fabbri G; Monopoli A; Rossi D; Matassi L; Strazzulla G; Bisi G
    Cardiology; 1989; 76(1):32-41. PubMed ID: 2706643
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Verapamil-sustained release-based treatment strategy is equivalent to atenolol-based treatment strategy at reducing cardiovascular events in patients with prior myocardial infarction: an INternational VErapamil SR-Trandolapril (INVEST) substudy.
    Bangalore S; Messerli FH; Cohen JD; Bacher PH; Sleight P; Mancia G; Kowey P; Zhou Q; Champion A; Pepine CJ;
    Am Heart J; 2008 Aug; 156(2):241-7. PubMed ID: 18657652
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Age-related antihypertensive and haemodynamic effects of verapamil SR: clinical results and effects on atrial natriuretic peptide.
    Antonicelli R; Tomassini PF; Galletti P; Gambini C; Marini M; Amadio L; Paciaroni E
    Eur J Clin Pharmacol; 1990; 39 Suppl 1():S29-33. PubMed ID: 2148149
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of intravenous verapamil in arterial hypertension refractory to three-step antihypertensive therapy.
    Gurgenian SV; Mikaelian ES; Dzhandzhapanian AZ; Babaian AS
    Cor Vasa; 1991; 33(5):397-403. PubMed ID: 1810700
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The effect of verapamil on cardio- and hemodynamics in rats with various models of hypertension].
    Spasov AA; Gurbanov KG; Seredintseva NV; Paperno AA
    Eksp Klin Farmakol; 1997; 60(3):30-3. PubMed ID: 9324394
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.